" /> Brentuximab Vedotin - CISMeF





Preferred Label : Brentuximab Vedotin;

NCIt synonyms : Anti-CD30 Monoclonal Antibody-MMAE SGN-35; Anti-CD30 Antibody-Drug Conjugate SGN-35; Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35; cAC10-vcMMAE;

NCIt definition : An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.;

UNII : 7XL5ISS668;

CAS number : 914088-09-8;

Drug name : Adcetris;

Molecule name : SGN-35; ADC SGN-35; SGN 35;

Chemical formula : C68H106N11O15S;

Codes from synonyms : 77;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
08/07/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.